

CalPERS Biosimilar Experience
Melissa Mantong, PharmD, MS, FCSHP
Pharmaceutical Consultant II

August 12, 2020

CalPERS Background Information

(2017 Data)

1,437,000 Members (1,172,000 Basic, 266,000 Medicare)

\$2.15B Total Drug Spend (\$1.25B Basic, \$880M Medicare)

\$828.3M in Specialty Drugs (\$516.9M Basic, \$311.4M Medicare)

\$521.7M in Medical Pharmacy (\$317.3M Basic, \$204.4M Medicare)

Source: https://www.calpers.ca.gov/docs/board-agendas/201809/pension/item-5c-attach-2_a.pdf
<https://www.calpers.ca.gov/docs/forms-publications/health-benefits-program-annual-report-2019.pdf>

Biosimilar First Program

- Phase 1 Implementation – January 1, 2021

Infliximab biosimilar first for new adult patients in our PPO health plans.

- Current US biosimilar market share data by IQVIA

Filgrastim	Neupogen (48.0%)	Zarxio (31.7%)	Granix (20.3%)	Nivestym (0%)
Infliximab	Remicade (96.4%)	Inflectra (3.2%)	Renflexis (0.4%)	
Pegfilgrastim	Neulasta Onpro (61.0%)	Neulasta (38.2%)	Fulphila (0.8%)	

<https://www.journalofclinicalpathways.com/news/iqvia-data-show-biosimilars-struggling-market-share-us>

Our Journey

Q3 2018

- Initiated conversations with manufacturers
- Began data analysis

Q1 2019

- Established Biosimilar First Strategy
- Brainstormed adoption strategy

Q2 2019

- Began implementation planning - 1/1/2020
- Shifted coverage to PBM

Q3 2019

- Revised scope – kept coverage in health plan
- Created new implementation plan

Q4 2019

- Changed implementation date to 7/1/2020

Our Journey

Q3 2018

- Initiated conversations with manufacturers
- Began data analysis

Q1 2019

- Established Biosimilar First Strategy
- Brainstormed adoption strategy

Q2 2019

- Began implementation planning - 1/1/2020
- Shifted coverage to PBM

Q3 2019

- Revised scope – kept coverage in health plan
- Created new implementation plan

Q4 2019

- Changed implementation date to 7/1/2020

Our Journey

Q3 2018

- Initiated conversations with manufacturers
- Began data analysis

Q1 2019

- Established Biosimilar First Strategy
- Brainstormed adoption strategy

Q2 2019

- Began implementation planning - 1/1/2020
- Shifted coverage to PBM

Q3 2019

- Revised scope – kept coverage in health plan
- Created new implementation plan

Q4 2019

- Changed implementation date to 7/1/2020

Our Journey

Q3 2018

- Initiated conversations with manufacturers
- Began data analysis

Q1 2019

- Established Biosimilar First Strategy
- Brainstormed adoption strategy

Q2 2019

- Began implementation planning - 1/1/2020
- Shifted coverage to PBM

Q3 2019

- Revised scope – kept coverage in health plan
- Created new implementation plan

Q4 2019

- Changed implementation date to 7/1/2020

Considerations and Barriers



Strategy alignment with Health Plan



Health Plan system limitations



Medical benefit complexity